Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Hepatocyte Growth Factor for Opioid-Dependent Pain: Efficacy and Safety of VM202 in Painful Diabetic Peripheral Neuropathy (The HOPES Trial)

NCT04087941 is registered in ClinicalTrials.gov with Brigham and Women's Hospital as lead sponsor.

NCT NCT04087941
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04087941 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Hepatocyte Growth Factor for Opioid-Dependent Pain: Efficacy and Safety of VM202 in Painful Diabetic Peripheral Neuropathy (The HOPES Trial)
Lead sponsor
Brigham and Women's Hospital
Phase
Phase 2
Overall status
Withdrawn
Start date
November 30, 2019
Completion date
December 31, 2022
Enrollment
0 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

painful diabetic neuropathy